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Background: The Ethiopian epidemic is currently on the wane. However, the situation for infected children is in some
ways lagging behind due to low treatment coverage and deficient prevention of mother-to-child transmission. Too
few studies have examined HIV infected children presenting to care in low-income countries in general. Considering
the presence of local variations in the nature of the epidemic a study in Ethiopia could be of special value for the
continuing fight against HIV. The aim of this study is to describe the main characteristics of children with HIV presenting
to care at a district hospital in a resource-limited area in southern Ethiopia. The aim was also to analyse factors affecting
pre-ART loss to follow-up, time to ART-initiation and disease stage upon presentation.
Methods: This was a prospective cohort study. The data analysed were collected in 2009 for the period January 2003
through December 2008 at Arba Minch Hospital and additional data on the ART-need in the region were obtained
from official reports.
Results: The pre-ART loss to follow-up rate was 29.7%. Older children (10–14 years) presented in a later stage of
their disease than younger children (76.9% vs. 45.0% in 0–4 year olds, chi-square test, χ2 = 8.8, P = 0.01). Older girls
presented later than boys (100.0% vs. 57.1%, Fisher’s exact test, P = 0.02). Children aged 0–4 years were more likely
to be lost to follow-up (40.0 vs. 21.8%, chi-square test, χ2 = 5.4, P = 0.02) and had a longer time to initiate ART
(Cox regression analysis, HR: 0.50, 95% CI: 0.25-0.97, P = 0.04, controlling for sex, place of residence, enrolment
phase and WHO clinical stage upon presentation). Neither sex was overrepresented in the sample. Tuberculosis
prevalence upon presentation and previous history of tubercolosis were 14.5% and 8% respectively.
Conclusions: The loss to follow-up is alarmingly high and children present too late. Further research is needed to
explore specific causes and possible solutions.
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Recent global reports suggest considerably improved ac-
cess to antiretroviral therapy (ART) in low and middle-
income countries including in Sub-Saharan Africa. Ac-
cording to the 2013 global report, 9.7 million patients
were receiving life-saving ART by the end of 2012 [1].
This is a remarkable acheivement as compared to a dec-
ade earlier when less than half a million patients were
on ART in low and middle-income countries [2]. How-
ever, these gains in access are being challenged by* Correspondence: emil.a.westerlund@gmail.com
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article, unless otherwise stated.emerging set of problems, one of which being retaining
patients in care. A recent systematic review revealed
problems with patient retention both before and after
initiating ART [3]. This challenge and its associated fac-
tors are more clearly delineated in adult patient popula-
tions than in children.
During 2011, about 24 000 new infections were re-
ported to have occurred and there were around 790 000
people infected with HIV living in Ethiopia, which is
1.5% of the entire population. The latter prevalence is
projected to decline as well, along with mortality and in-
cidence [4]. These encouraging results are believed to be
the effect of concerted local and global actions includingtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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decentralization, and task shifting [5,6]. The challenge
of poor linkage to and retention in care has been well
recognized in the Ethiopian HIV program. Published
studies from Arba Minch and Gondar hospitals, for
example, suggest high rates of pre-ART patient loss among
adult patients living with HIV [6,7]. As elsewhere, there is
limited information on the challenges of pre-ART patient
retention among children living with HIV in Ethiopia [2].
Despite the success, many challenges still prevail [2,8].
There are problems with low condom use, violence against
women and stigma leading to loss of job and income. One
in five Ethiopians with HIV experience suicidal feelings.
Another major problem is the low coverage of antiretroviral
regimens to prevent mother-to-child transmission and rates
of infant testing and prophylaxis remain very low [2,9].
Some of the most worrying statistics on HIV in Ethiopia
concern the health of children. The deficient prevention
of mother-to-child transmission in Ethiopia is central to
the problem of HIV among children. Ethiopian studies
have shown, similarly to findings from other low-income
countries and international reports, that a majority of chil-
dren with HIV in the country have acquired their infection
vertically [9-11]. Apart from this, a big problem is the low
ART coverage for children. Although the data are currently
under review and may reveal an improvement, reports from
2010 announce that only 14–38% of the ART-need among
children is met [9].
For those children who do present to care, further
problems ensue. Timely initiation of treatment and reten-
tion in care are both crucial for patient outcome [12,13].
Late presentation to care among children have been identi-
fied as a problem in both high-income and low-income
countries [11,14]. This implies that children in low-income
countries are put in a particularly vulrerable situation as
late presentation has been shown to be also a general prob-
lem in Sub-Saharan Africa [6,15]. A review from 2009 has
found the reasons for this to be mainly population-based
barriers to access such as lack of information, stigma and
perceived high cost of treatment. However, the reviewer
stresses that ‘there is a paucity of studies on access barriers
to ART for HIV-positive children’ [16]. Furthermore, not all
studies show that children present late. For instance, a
study from India showed that children below 14 years of
age actually were associated with a lower risk of late
presentation [17]. This further underscores the import-
ance of more local research. Extending the knowledge
on HIV-infected children presenting to care in Ethiopia
is critical for not letting children lag behind in the
process to overcome the epidemic.
In this report, we present data from one of the longest-
followed cohorts of paediatric HIV patients on TB preva-
lence and the magnitude and predictors of retention in
care. The aim of this study was to describe the maincharacteristics and to analyze the predictors of pre-ART
loss to follow up among children with HIV presenting to
care at a district hospital in a resource-limited area in
southern Ethiopia.
Methods
Participants
The data were collected at Arba Minch Hospital in south-
ern Ethiopia. The hospital is a general public hospital lo-
cated in the city of Arba Minch, in the Southern Nations,
Nationalities, and People’s Region (SNNPR), around 500
kilometres south of Addis Ababa, Ethiopia’s capital. Arba
Minch Hospital was the first hospital to introduce anti-
retroviral treatment in SNNPR in 2003—at a time when
there were only few such centres in Ethiopia. The hospital
serves a population of over 1.5 million in the Gamo Goffa
zone of SNNPR. We established the HIV cohort database
in 2003 and maintained it through this date. Since this is
the longest-followed cohort in Ethiopia and resource
constraint did not allow us to establish more of such cen-
tres, we opted to continue with analysis and learning from
our existing cohort. This study did not entail any active
data collection. We used de-identified data from the exist-
ing database and restricted our analysis to the paediatric
age group as most of our earlier analyses did not involve
this age group. All children with HIV presenting to
care at Arba Minch Hospital from January 2003
through December 2008 were included in this study.
The inclusion criteria were to be under 15 years old
and to have an HIV infection. Children with a previous
history of ART were excluded.
Procedure of therapy and data collection
The data for this study were collected along with data for
adult patients at the same hospital. The findings on those
data have been published elsewhere and the method
described below is in part described in that study as well
[6]. A trained health care worker did the initial evaluation
and subsequent follow-up of the patients. During the ini-
tial years of the study this evaluation was made using only
clinical and total lymphocyte count (TLC) criteria. From
mid-2006 and onward CD4 testing was also available. The
patients started ART according to the national guidelines
issued by the Ethiopian Ministry of Health (MOH), which
issued updated versions of the guidelines during the
course of this study.
The first Ethiopian ART guidelines were published
in 2003 and the paediatric treatment guidelines were
included as a chapter in the adult guidelines. The first
paediatric ART guidelines were published in 2008
and the recommendations did not change since then.
Accordingly, treatment is recommended for all infants with
confirmed HIV infection. Treatment is recommended for
older children with stage III or IV diseases irrespectively of
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ease a table is used as a guide outlining different CD4
count/percentage thresholds for different ages (12–35
months: < 750 cells/mm3 or < 20%, 36–59 months: < 350
cells/mm3 or < 20%, 5 years or older - same as adults: < 200
cells/mm3 or < 15%). These thresholds did slightly change
during the course of the study. In the 2003 guidelines the
15% threshold extended down to children of 18 months
and the adult thresholds were applied to children 8 years or
older. The guidelines also specify how to assess HIV infec-
tion and disease stage clinically if proper laboratory tests
are unavailable [18-20].
Two data clerks recorded patient information both on
paper and electronically. With a data abstraction form as a
guide they recorded variables directly into an SPSS file.
These variables include date of HIV-testing, date of pre-
ART enrolment, WHO clinical stage, total lymphocyte
count (TLC), CD4 count, haemoglobin level (HGB), history
of TB (as reported by patient or caregiver), current TB
(diagnosed within one month before or after presentation),
sex, age, place of residence (rural or urban), pre-ART
outcome and date of ART-initiation (if initiated).
During most of the time of the study, there was no strict
guideline for pre-ART follow-up schedule neither for
adults nor for children. Patients at the hospital were told
to return after 3–6 months depending on their clinical
condition. The 2008 paediatric guidelines formalised the
schedule to recommend follow-up every 1–3 months
depending on age and clinical condition (or more fre-
quently than monthly if clinically indicated) [20]. How-
ever, there was no recording and reporting mechanism
for the pre-ART visits and definitions for pre-ART out-
comes such as loss to follow-up was not formalized.
The Ethiopian Ministry of Health has recently finalized
a nation-wide assessment of the status of pre-ART
patient care. It is expected to lead to development of a
comprehensive national framework for pre-ART care. In
the mean time, we continued to use our own operational
definition for pre-ART care. The pre-ART outcome was
defined as: (a) ‘still under pre-ART care’ – if the patient
was registered with the ART clinic of the hospital, had
regular follow-up with the clinic and was not having fol-
low up at another health facility; (b) ‘lost to follow-up’ – if
patient did not have a follow-up visit at least 30 days after
the last date of the most recent clinic appointment; (c) ‘put
on ART’ – if patient was started on ART in the hospital
clinic; (d) ‘died before starting ART’ – if patient was known
to be dead as reported by treating clinicians or community
health agents; and (e) ‘transferred out’ – if patient moved
to another health facility with confirmed written docu-
mentation of transfer out.
For those patients that were put on ART, patients were
defined as lost to follow-up if they had not attended the
hospital within 30 days following the time for theirclinical appointment. For patients lost to follow-up an
extended follow-up was conducted in 2009 and involved a
home visit or phone call using community health agents.
Patient status after extended follow-up was defined as (a)
‘died’ – if a family member, neighbour or community
leader reported death of the patient; (b) ‘under follow up
at another health facility’ – if the patient was on treatment
at any health facility in the region as reported by family,
neighbours or community leaders; (c) ‘stopped treatment
but alive’ – if the patient had not taken antiretroviral
drugs (ARVs) for over a month and the patient was
alive and did not get ART elsewhere; (d) ‘on traditional
treatment’ – if the patient reported that he or she used
traditional medicines or treatment instead of ART and
(e) ‘left the region’ – if patient left the region as
reported by family, neighbours or community leaders.
If no information was available about the patient, this
was defined as (f ) ‘unknown’ (‘true loss’).
Patient data were updated at each visit. The database
was updated on a quarterly basis 2003–2006 and yearly
the last two years. In 2009, we undertook a more thorough
cohort updating that involved home visits to determine
the status of each patient declared to be lost as described
above. The recorded data were updated, amended and
cross-checked with paper records at the hospital in order
to affirm their quality. In addition to the patient data, data
on ART-need among girls and boys in SNNPR were
obtained from an official report for statistical comparison
with data on the participants of the study [4].
Ethics
The prospective cohort follow up system at Arba Minch
hospital was established with the approaval of the the
National Research Ethics Review Committee in Ethiopia.
All patients were given standard care at the hospital, as
prescribed in the national guidelines [18,19].
This particular analysis was done based on a separate
protocol specifically designed to look into long-term treat-
ment outcomes including pre-ART outcomes for which
separate local approval was sought and granted. Since we
used de-identified data for this analysis, obtaining patient
consent was not feasible but permission was obtained from
the hospital administration.
Statistical methods
SPSS was used for the analyses presented in this study. The
data was entered into SPSS version 16 and later transferred
to SPSS version 21. All data used for describing cohort
profile and baseline characteristics were obtained from the
SPSS file.
Data were grouped into three cohorts based on date
of enrolment to pre-ART care and the chronology of
Ethiopia’s ART scale-up [5]. The three cohorts were
decided to be (i) those enrolled January 2003-August 2006
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2007 (Rapid scale-up cohort) and (iii) those enrolled
between September 2007-December 2008 (Recent cohort).
For each cohort the proportion of patients presenting
in the different WHO clinical stages of HIV/AIDS was
compared. For the sake of clarity, a comparison was
also made with the WHO clinical stage dichotomized into
less advanced (stages I & II combined) and advanced
(stages III and IV). In regard to the small sample size these
distributions were only described for each cohort separately
and no trend analyses were performed.
Logistic regression including the dichotomized WHO
stage variable was used to identify potential risk factors
for being in an advanced stage upon presentation. Because
of the small sample size only four variables were screened:
age, sex, place of residence and cohort. These variables
were chosen on bases of biological and social plausibility
and on the findings from the adult cohort [6]. A similar
logistic regression was used to determine risk factors for
being lost to pre-ART follow-up and the same variables
were chosen for this analysis. Individual chi-square tests
were performed to further analyse factors found to affect
pre-ART loss and late presentation. For one analysis
where the criteria for performing a chi-square test were
not deemed to be met, Fischer’s exact test was done
instead.
Student’s T test was used to determine whether the
distribution between boys and girls presenting to care
was significantly different from the distribution among
HIV-infected children in general. Estimates for these
numbers were obtained from official reports on the
region, issued by the Ethiopian Ministry of Health [4].
Time to ART-initiation for different age groups was
estimated using Cox regression, controlling for sex, place of
residence, enrolment phase and WHO clinical stage upon
presentation. Statistical significance was defined as P < 0.05.
The research adhered to strengthening the reporting
of observational studies in epidemiology (STROBE)
guidelines [21] (See Additional file 1 for more details).
Results
Cohort profile
Out of the 139 children who initiated pre-ART care from
January 2003 through December 2008 all but one were
enrolled in the study. The child who was not enrolled
had a history of previous ART and thus failed to meet
the inclusion criteria. Out of the 138 children included,
79 (57.2%) were put on ART, 15 (10.9%) were still under
pre-ART care at the time of follow up, two (1.4%) had
been transferred out of the hospital and one child (0.7%)
had died. The remaining 41 children (29.7%) were lost
to follow-up (Figure 1).
Of the 79 children who were put on ART, a majority
was still enrolled in treatment at the time of follow-up,namely 65 children (82.3%). Five children (6.3%) had died,
one (1.3%) had been transferred out and one had stopped
treatment. The remaining 7 children (8.9%) were lost to
follow-up. Three of these children were living in urban
addresses and were traced for an extended follow-up. One
had died and another was alive, receiving traditional treat-
ment at ‘holy water’. The outcome of the last child
remains unknown.
The 138 patients enrolled in the study contributed 175.9
person years of observation (PYO). The median time to
pre-ART outcome was 1.1 months (IQR: 0.2-6.1) and the
median time from ART initiation to ART outcome (for the
79 patients put on ART) was 23.3 months (IQR: 5.1-30.1).
Characteristics of the children
The characteristics of the 138 children upon enrolment
to pre-ART care are shown in Table 1. Their median
age was 5 years (IQR: 3–8); 60 children (43.5%) were
0–4 years old, 52 children (37.7%) were 5–9 years old
and 26 children (18.8%) were 10–14 years old. As for
distribution between sexes, there were 79 boys (57.0%)
in the entire sample. A vast majority of 121 children
(87.7%) were urban residents and the remaining 17
(12.3%) had rural addresses. A previous history of TB
was found for 11 children (8.0%) while 20 children
(14.5%) had a TB infection upon presentation. CD4
count was recorded for 97 patients and the mean value
was 529 cells/mm3.
Differences between age groups
The distribution of presenting stage for different age
groups is shown in Table 2. There were 26 children aged
10–14 years, 6 (23.1%) of these presented in a less
advanced stage while the remaining 20 (76.9%) presented
in an advanced stage. The higher proportion of children
presenting late in the oldest age group was found to be
statistically significant when compared to the reference
group of 0–4 year olds (Chi-square test, χ2 = 8.8, P = 0.01).
No significant difference was found between the middle
and the youngest age group.
Pre-ART loss to follow-up proportion within different
age groups is shown in Table 3. Among the 78 children
who were 5 years or older, 17 (21.8%) were lost to
follow-up. The number of children lost to follow-up
among the 60 children aged 0–4 years was 24 (40.0%), a
significantly higher proportion compared to the older
children. (Chi-square test, χ2 = 5.4, P = 0.02).
Risk factors for longer time to ART initiation
The 138 patients enrolled in the study contributed 47.0
person years of observation (PYO) in pre-ART follow-up.
The median time to ART initiation for all participants was
18 days (IQR 6–113). When controlling for sex, place of
residence, enrolment phase and WHO clinical stage upon
Table 1 Presenting characteristics of children, Arba Minch
Hospital, Ethiopia
Characteristic Number (%)
Age 0-4 years 60 (43.4)
5-9 years 52 (37.7)
10-14 years 26 (18.8)
Sex Female 59 (42.8)
Male 79 (57.2)
Place of residence Urban 121 (57.2)
Rural 17 (12.3)
WHO clinical stage Stage I 31 (22.5)
Stage II 37 (26.8)
Stage III 59 (42.8)
Stage IV 11 (8.0)
Past history of TB Yes 11 (8.0)
No 127 (92.0)
TB upon presentation Yes 20 (14.5)
No 118 (85.5)
Characteristic Central tendency (variation)
CD4 count* Mean 529 cells/mm3
Hgb** Mean 10.7 g/dl
Time to ART*** Median (IQR) 18 days (6–113)
*97 cases analysed, 41 missing.
**101 cases analysed, 37 missing.
***For 79 patients put on ART.
Presenting characteristics for 138 children with HIV at Arba Minch Hospital,
who initiated pre-ART care during the period 2003–2008.
Figure 1 Cohort profile. Cohort profile of children treated at Arbaminch Hospital during the period 2003–2008, Arba Minch, Ethiopia.
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0–4 years waited longer to initiate ART (HR: 0.50, 95% CI:
0.25-0.97, P = 0.04).
A longer time to ART initiation was also found for
children presenting in stage I (HR: 0.27, 95% CI: 0.09-
0.80, P = 0.02). Table 4 shows the adjusted hazard
ratios for all variables mentioned above and Figure 2
shows the survival curves according to Cox regression
with separate lines for different age groups.
Differences between sexes
The proportion of patients presenting in an advanced
stage (in either stage III or stage IV) for boys and girls re-
spectively is presented in Table 5. Out of the 59 girls in
the sample, 35 (59.3%) presented in an advanced stage; for
the boys the number was 35 (44.3%) out of 79. The table
also shows sex difference in presenting stage stratified by
different age groups. For ages 10–14, all 12 (100.0%) of the
girls presented late, as compared to 8 (57.1%) out of the 14
boys and this distribution was determined to be statistically
significant (Fisher’s exact test, P = 0,02). However, the
sample size was critically small for further statistical evalu-
ation. The sex differences for the other two age groups
were not statistically significant, neither was the difference
between sexes for all age groups combined.
Neither boys nor girls were found to be overrepresented
at the clinic. According to official reports, the proportion
of girls in need of ART in SNNPR was 49.7% in 2011. It
was not possible to obtain this proportion for the actual
period studied (2003–2008) but the proportion was not
Table 2 Presenting stage of HIV/AIDS for different age groups
Less advanced (%) Advanced (%) Total χ2 significance
0-4 years* 33 (55.0) 27 (45.0) 60 -
5-9 years 29 (55.8) 23 (44.2) 52 P > 0.05
10-14 years 6 (23.1) 20 (76.9) 26 P = 0.01
*reference category.
Less advanced = Stage I & II combined.
Advance = Stage III & IV combined.
Presenting stage of HIV/AIDS for different age groups in a cohort of 138 children who initiated pre-ART care during the period 2003–2008.
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estimated decrease in total numbers [4]. On these grounds
it was assumed that the proportion was similar during the
period of the study. The proportion of girls in the sample
was 43.0% – 6.7 percentage points lower than girls in need
of ART in the region – but this difference was not found to
be significant for P < 0.05 (two-tailed significance, P = 0.10).
Changes after the scale-up of ART
WHO clinical stage for children presenting to care at
Arba Minch Hospital during the three phases of ART
scale-up in Ethiopia is shown in Table 6. In the early
phase, 17 (41.5%) out of 41 children presented in a less
advanced stage, a proportion which in the recent phase
rose to 35 (59.3%) out of 59 children. Due to the small
size of the sample, an analysis to assess whether this
trend was significant was not performed.
Discussion
This study shows that older children present later to
care and that among the older children, girls present
later than boys. Younger children face other problems, as
they are shown to have a longer waiting time to initiate
ART and to be more likely to discontinue their pre-ART
program. The overall percentage of pre-ART loss to
follow-up is alarmingly high and a notable TB prevalence
(14,5%) is seen upon presentation. No sex difference was
found in presentation to care among the children in need
of ART in the region.
Another study was conducted on HIV-infected adults
presenting to care at Arba Minch Hospital during the
same period as the children participating in this study.
In the adult cohort consisting of 2191 patients, 25% were
lost to pre-ART follow-up [6]. As was discussed earlier,
the ART coverage of children in Ethiopia is lower than
that of adults [22]. This fact together with the loss to
follow-up reported for adults at the same hospital
suggest a worrying pattern where children not only haveTable 3 Pre-ART loss to follow-up for different age groups
Not lost to follow-up (%) Lost
0-4 years 36 (60.0) 24 (4
5-14 years 61 (78.2) 17 (2
Loss to follow-up for different age groups in a cohort of 138 children who initiatedless access to care but also continue care to a lesser
extent than adults. A likely explanation for this is the
fact that the children presenting to care in this study
were generally healthier (in a less advanced stage of
HIV) than the adults but even so the issue ought not be
disregarded. It is however worth noting that the new
WHO guidance of starting ART for all children under 5
has been endorsed by the Ethiopian Ministry of Health
but its cost and associated implications are being studied
before its implementation. If implemented, this new
guidance may alleviate some of the concerns noted in
this study.
It may not be surprising that older children presented
later. Studies from around world show that – although
figures vary slightly in different settings – a majority of HIV
infected children anywhere have acquired their infection
vertically. If this is the case also for the area serviced by
Arba Minch Hospital, it would mean the disease had had
longer time to progress in the children aged 10–14 years.
Yet, if perinatal transmission is indeed the dominating
mode among these children, it is still troubling that so
many cases go undiscovered so long – one in five being
over 9 years old and the better part being 5 years or older.
This is not unique for Ethiopia. Age distributions such
as these have been reported elsewhere in low-income
countries; a recent Ugandan study showed roughly
similar proportions at two different district hospitals
and children’s ages were also high in a large Indian
cohort [23,24]. The fact that older children present later
could also be part of the explanation why younger chil-
dren are lost to pre-ART follow-up more frequently, as be-
ing in a less advanced stage has been shown elsewhere to
be a predictor for pre-ART loss to follow-up [6].
As for the older girls presenting later than the older
boys, potential explanations are less obvious. Studies on
adults have actually reported women in Sub-Saharan
Africa to present earlier than men, but additional factors
associated with early presentation are pregnancy andto follow-up (%) Total χ2 significance
0.0) 60 P = 0.02
1.8) 78
pre-ART care during the period 2003–2008.
Table 4 Factors associated with longer waiting time to ART initiation, Arba Minch Hospital, Ethiopia
Variable Adjusted HR (95% CI) P-value
Sex Male vs Female 0.90 (0.57-1.42) >0.05
Address Rural vs Urban 0.98 (0.46-2.05) >0.05
Phase of enrolment Early phase 1.36 (0.78-2.37) >0.05
Rapid scale-up 1.09 (0.59-2.00) >0.05
Recent phase* 1.00
Age group 0-4 years 0.50 (0.25-0.97) 0.04
5-9 years 0.40 (0.42-1.41) >0.05
10-14 years* 1.00
WHO clinical stage Stage I 0.27 (0.09-0.80) 0.02
Stage II 0.69 (0.27-1.71) >0.05
Stage III 0.88 (0.38-2.04) >0.05
Stage IV* 1.00
*reference category.
Hazard ratios for factors associated with having a longer time to ART initiation in a cohort of 138 children who initiated pre-ART care during the
period 2003–2008.
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naturally less occurrent among younger girls. Younger
girls are also much less likely to be married, and being
single is associated with presenting late not only in general
but especially for women [15]. This kind of extrapolation
however is somewhat speculative and probably does not
tell the whole story.
On the other hand, previous research may provide a
more straightforward explanation for the high loss to
follow-up and longer waiting times among the youngestFigure 2 Time to ART for different age groups. Survival curves
according to Cox regression analysis showing time to ART initiation
for different age groups controlling for sex, place of residence,
enrolment phase and WHO clinical stage upon presentation. Survival
times for patients not reaching the event during the time of their
observation (censored data) are also accounted for in the figure.children. One reason that sufficient adherence can be
hard to achieve for children is that they have to rely on
their caregivers for it, caregivers who are often themselves
in poor health due to HIV or difficult social circumstances
[25]. The youngest children being most reliant on adults,
this could explain their low retention. It could also explain
the longer waiting time, since it is not recommended to
initiate ART before it has been properly established that
the patient is likely to adhere to the treatment [18,19].
TB is the leading cause of death for people living with
HIV and ART has been shown to substantially reduce
the incidence of TB [22,26]. Therefore it is important to
note the high rates of previous and current TB infection
among the children presenting to care. Sadly, these
findings are not that surprising, seeing that high rates have
been reported in other child cohorts from low-income
countries [11,25,27]. In any event, the findings underline
the importance of earlier initiation of ART and generally
improving collaborative TB-HIV care.
The main limitation of this study is the small sample
size. Due to this fact, changes in presenting stage and
mortality after the rapid scale-up of ART could not be
analysed properly. This is unfortunate since these and other
factors may have improved as a result of the scale-up, as
has been shown for the adult cohort. On some instances
when analyses were made on sub-groups of the entire
cohort the sample size was even smaller. Therefore the
finding that older girls present later than boys should be
interpreted with caution. The large number of tests
performed on this rather small sample also increases the
risk of finding false significance and this should be taken
into consideration.
Another limitation of this study was that the circum-
stances of data collection did not allow for a separate
Table 5 Sex difference in presenting stage of HIV/AIDS
Less advanced (%) Advanced (%) Total Significance
All ages Girls 24 (40.6) 35 (59.3) 59
Boys 44 (55.6) 35 (44.3) 79
0-4 years Girls 11 (47.8) 12 (53.2) 23 P > 0.05a
Boys 22 (59.5) 15 (40.5) 37
5-9 years Girls 13 (54.2) 11 (45.8) 24 P > 0.05a
Boys 16 (57.1) 12 (42.9) 28
10-14 years Girls 0 (0.0) 12 (100.0) 12 P = 0.02b
Boys 6 (42.9) 8 (57.1) 14
aChi-square significance test.
bFisher’s exact test.
Less advanced = Stage I & II combined.
Advanced = Stage III & IV combined.
Sex difference in presenting stage of HIV/AIDS stratified by age group in a cohort of 138 children who initiated pre-ART care during the period 2003–2008.
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Information on parents’ infections and social status, mea-
sures of prevention during pregnancy, mode of delivery and
nutritional status of the child would have been valuable
supplements for the analyses.
The range of problems seen in the provision of ART and
retention in care all point to the same basic conclusion:
reducing the rate of mother-to-child transmission is key
to improving the paediatric HIV situation in Ethiopia.
More research is needed to assess how perinatal care for
infected women as well as testing of and prophylaxis for
infants can be improved upon.
Nonetheless in addition to this, as long as there are still
children infected with HIV, the detection of and care for
these children need improvement as well. More re-
search should explore the factors associated with loss
to follow-up, late presentation, not presenting to care at
all and possible interventions to solve these problems.
Although likely candidates have been suggested in this
discussion for the most immediate causative factors, there
are likely also more general social factors such as poverty
that put children at risk for lower access to care, lower
adherence and unfavourable disease outcome. For this
reason, more social research in addition to purely medical
research would be welcome. To determine changes over
time in pre-ART and on-ART loss to follow-up, mortality
and presenting stage among children, research on largerTable 6 Presenting stage during the different phases of
ART scale-up
Less advanced (%) Advanced (%) Total
Early phase 17 (41.5) 24 (58.5) 41
Rapid scale-up phase 16 (42.1) 22 (57.9) 38
Recent phase 35 (59.3) 24 (40.7) 59
Less advanced = Stage I & II combined.
Advanced = Stage III & IV combined.
Presenting stage during the different phases of ART scale-up in a cohort of
138 children who initiated pre-ART care during the period 2003–2008.Ethiopian cohorts of children is of crucial importance in
the future.
Some inequalities between patient groups described in
this study may still be prevalent despite the general im-
provement after the ART scale-up. Thus, even though our
data are by now a few years old the results are nonetheless
relevant in this respect and hopefully our findings will also
serve a purpose for comparison with the contemporary
adult cohort, as well as with future studies of this kind.Conclusions
Although the sample size in this study was too small to
make some important analyses on how the situation has
developed over time, a number of problems have been
identified concerning HIV-infected children presenting to
care. The main ones are high pre-ART loss to follow-up
rate, high TB prevalence and late presentation. Reasons for
the higher loss to follow-up and longer waiting time to
initiate treatment among the youngest children need to be
further investigated. So do potential reasons for older girls
presenting later than older boys and also general social
factors that could be associated with several of these
problems.Additional file
Additional file 1: STROBE 2007 (v4) Statement—Checklist of items
that should be included in reports of cohort studies.
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